BRPI0912411A2 - uso de uma muteína de interleucina humana-2 (muteína de hil-2) ou de um fragmento da mesma, composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune, uso de muteína de interleucina humana-2 (muteína de hil-2) ou de uma seção da mesma, agete para formação de células t regulatórias (treg) em um organismo, método para tratamento e/ou profilaxia de uma doença autoimune em um organismo, método para formação de células t regulatórias (treg) em um organismo, método para formação de células t regulatórias (treg) in vitro. - Google Patents

uso de uma muteína de interleucina humana-2 (muteína de hil-2) ou de um fragmento da mesma, composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune, uso de muteína de interleucina humana-2 (muteína de hil-2) ou de uma seção da mesma, agete para formação de células t regulatórias (treg) em um organismo, método para tratamento e/ou profilaxia de uma doença autoimune em um organismo, método para formação de células t regulatórias (treg) em um organismo, método para formação de células t regulatórias (treg) in vitro.

Info

Publication number: BRPI0912411A2
Authority: BR; Brazil
Prior art keywords: mutein; organism; treg; regulatory; cells
Prior art date: 2008-05-08

Application number

BRPI0912411A

Other languages

English (en)

Inventor

Daniela Paulsen

Dorothy Bray

Nina Brunner

Original Assignee

Aicuris Gmbh & Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-08

Filing date

2009-04-28

Publication date

2016-09-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41152787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0912411(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-04-28 Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg

2016-09-13 Publication of BRPI0912411A2 publication Critical patent/BRPI0912411A2/pt

2019-05-14 Publication of BRPI0912411A8 publication Critical patent/BRPI0912411A8/pt

2020-02-18 Publication of BRPI0912411B1 publication Critical patent/BRPI0912411B1/pt

2021-05-25 Publication of BRPI0912411B8 publication Critical patent/BRPI0912411B8/pt

Links

230000015572 biosynthetic process Effects 0.000 title 3
238000000034 method Methods 0.000 title 3
210000003289 regulatory T cell Anatomy 0.000 title 3
208000023275 Autoimmune disease Diseases 0.000 title 2
101100506090 Caenorhabditis elegans hil-2 gene Proteins 0.000 title 2
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 title 2
102000055277 human IL2 Human genes 0.000 title 2
238000011321 prophylaxis Methods 0.000 title 2
238000011282 treatment Methods 0.000 title 2
239000012634 fragment Substances 0.000 title 1
238000000338 in vitro Methods 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A61K40/4272—Melan-A/MART
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A61K40/4273—Glycoprotein 100 [Gp100]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Hematology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Mycology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Pulmonology (AREA)

BRPI0912411A 2008-05-08 2009-04-28 uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune BRPI0912411B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE102008023820.1		2008-05-08
DE102008023820A DE102008023820A1 (de)	2008-05-08	2008-05-08	Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
PCT/EP2009/003076 WO2009135615A2 (de)	2008-05-08	2009-04-28	Mittel zur behandlung und/oder prophylaxe einer autoimmunerkrankung und zur bildung von regulatorischen t-zellen

Publications (4)

Publication Number	Publication Date
BRPI0912411A2 true BRPI0912411A2 (pt)	2016-09-13
BRPI0912411A8 BRPI0912411A8 (pt)	2019-05-14
BRPI0912411B1 BRPI0912411B1 (pt)	2020-02-18
BRPI0912411B8 BRPI0912411B8 (pt)	2021-05-25

Family

ID=41152787

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0912411A BRPI0912411B8 (pt)	2008-05-08	2009-04-28	uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune

Country Status (28)

Country	Link
US (4)	US20110150826A1 (pt)
EP (1)	EP2288372B1 (pt)
JP (2)	JP5651583B2 (pt)
KR (3)	KR101554056B1 (pt)
CN (2)	CN102088996A (pt)
AR (1)	AR071756A1 (pt)
AT (1)	ATE544465T1 (pt)
AU (1)	AU2009244039B2 (pt)
BR (1)	BRPI0912411B8 (pt)
CA (1)	CA2723761C (pt)
CL (1)	CL2009001099A1 (pt)
CY (1)	CY1112469T1 (pt)
DE (1)	DE102008023820A1 (pt)
DK (1)	DK2288372T3 (pt)
ES (1)	ES2378957T3 (pt)
HR (1)	HRP20120296T1 (pt)
IL (3)	IL209128A (pt)
MX (1)	MX2010012214A (pt)
PE (1)	PE20091967A1 (pt)
PL (1)	PL2288372T3 (pt)
PT (1)	PT2288372E (pt)
RU (1)	RU2531936C2 (pt)
SI (1)	SI2288372T1 (pt)
TW (1)	TWI510622B (pt)
UA (1)	UA102099C2 (pt)
UY (1)	UY31816A (pt)
WO (1)	WO2009135615A2 (pt)
ZA (1)	ZA201008129B (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102008023820A1 (de)	2008-05-08	2009-11-12	Aicuris Gmbh & Co. Kg	Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
MX2011007647A (es)	2009-01-21	2011-09-01	Amgen Inc	Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
US11090363B2 (en)	2009-07-10	2021-08-17	University of Pittsburgh—of the Commonwealth System of Higher Education	Vasoactive intestinal peptide release from microparticles
US8846098B2 (en)	2009-07-10	2014-09-30	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Artificial cell constructs for cellular manipulation
CU23734A1 (es) *	2009-11-27	2011-11-15	Centro Inmunologia Molecular	Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
US9018006B2 (en) *	2010-07-23	2015-04-28	The University Of Toledo	Stable Tregs and related materials and methods
CU23923B1 (es) *	2010-11-12	2013-07-31	Ct De Inmunología Molecular	Polipéptidos derivados de la il-2 con actividad agonista
KR102220006B1 (ko)	2011-03-11	2021-02-24	아시스땅스 퍼블리끄-오삐또 드 빠리	자가면역 - 관련 또는 염증성 장애를 치료하기 위한 저용량 ｉｌ２ 의 용도
ES2811624T3 (es)	2011-03-11	2021-03-12	Hopitaux Paris Assist Publique	Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico
US20140044675A1 (en)	2012-08-10	2014-02-13	Roche Glycart Ag	Interleukin-2 fusion proteins and uses thereof
EP3640375A3 (en)	2012-12-11	2020-07-29	Albert Einstein College of Medicine	Methods for high throughput receptor/ligand identification
KR102042246B1 (ko)	2014-02-06	2019-11-28	에프. 호프만-라 로슈 아게	인터류킨-2 융합 단백질 및 이의 용도
WO2016025385A1 (en) *	2014-08-11	2016-02-18	Delinia, Inc.	Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
MY188430A (en) *	2015-04-10	2021-12-08	Amgen Inc	Interleukin-2 muteins for the expansion of t-regulatory cells
US20170204154A1 (en)	2016-01-20	2017-07-20	Delinia, Inc.	Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
KR102687530B1 (ko) *	2016-05-04	2024-07-25	암젠 인크	T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
KR20190044029A (ko)	2016-05-18	2019-04-29	알버트 아인슈타인 컬리지 오브 메디슨, 인크.	변이체 pd-l1 폴리펩타이드, t-세포 조절 다량체 폴리펩타이드 및 이들의 사용 방법
CA3019005A1 (en)	2016-05-18	2017-11-23	Cue Biopharma, Inc.	T-cell modulatory multimeric polypeptides and methods of use thereof
US11077172B2 (en) *	2016-11-08	2021-08-03	Delinia, Inc.	IL-2 variants for the treatment of psoriasis
CN116970059A (zh)	2016-12-22	2023-10-31	库尔生物制药有限公司	T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en)	2017-01-09	2023-12-26	Cue Biopharma, Inc.	T-cell modulatory multimeric polypeptides and methods of use thereof
US12350303B2 (en) *	2017-02-03	2025-07-08	University of Pittsburgh—of the Commonwealth System of Higher Education	Oncolytic virus therapy
BR112019018915A2 (pt)	2017-03-15	2020-04-14	Pandion Therapeutics Inc	imunotolerância direcionada
IL269000B2 (en)	2017-03-15	2024-06-01	Cue Biopharma Inc	Methods for modulating an immune response
JP2020521452A (ja)	2017-05-24	2020-07-27	パンディオン・セラピューティクス・インコーポレイテッド	標的化免疫寛容
KR102164417B1 (ko)	2017-09-15	2020-10-13	주식회사 카인사이언스	치료제로서의 펩타이드의 용도
KR102219926B1 (ko)	2017-09-15	2021-02-25	주식회사 카인사이언스	치료제로서의 펩타이드의 용도
US20200299349A1 (en)	2017-11-21	2020-09-24	The Board Of Trustees Of The Leland Stanford Junior University	Partial agonists of interleukin-2
USRE50550E1 (en)	2017-12-06	2025-08-26	Pandion Operations, Inc.	IL-2 muteins and uses thereof
US10946068B2 (en)	2017-12-06	2021-03-16	Pandion Operations, Inc.	IL-2 muteins and uses thereof
US10174091B1 (en)	2017-12-06	2019-01-08	Pandion Therapeutics, Inc.	IL-2 muteins
US11319355B2 (en)	2017-12-19	2022-05-03	Xencor, Inc.	Engineered IL-2 Fc fusion proteins
WO2019131964A1 (ja) *	2017-12-27	2019-07-04	協和発酵キリン株式会社	Ｉｌ－２改変体
WO2019139896A1 (en)	2018-01-09	2019-07-18	Cue Biopharma, Inc.	Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2019158764A1 (en)	2018-02-16	2019-08-22	Iltoo Pharma	Use of interleukin 2 for treating sjögren's syndrome
JP7464530B2 (ja)	2018-03-28	2024-04-09	ブリストル－マイヤーズスクイブカンパニー	インターロイキン－２／インターロイキン－２受容体アルファ融合タンパク質および使用方法
WO2020007937A1 (en)	2018-07-03	2020-01-09	Iltoo Pharma	Use of interleukin-2 for treating systemic sclerosis
WO2020035482A1 (en)	2018-08-13	2020-02-20	Iltoo Pharma	Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
BR112021010983A2 (pt)	2018-12-21	2021-08-31	Jiangsu Hengrui Medicine Co., Ltd.	Variante de interleucina-2 humana ou seu derivado
EP3920899A2 (en)	2019-02-08	2021-12-15	The UAB Research Foundation	Immunotherapy for the treatment and prevention of inflammatory bowel disease
US20220168394A1 (en) *	2019-04-23	2022-06-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of inducing or restoring immune tolerance
IL322315A (en)	2019-05-14	2025-09-01	Provention Bio Inc	Methods and preparations for preventing type 1 diabetes
WO2020236875A1 (en)	2019-05-20	2020-11-26	Pandion Therapeutics, Inc.	Madcam targeted immunotolerance
CA3147757A1 (en)	2019-07-26	2021-02-04	Visterra, Inc.	Interleukin-2 agents and uses thereof
AU2020328038B2 (en)	2019-08-13	2025-10-09	Amgen Inc.	Interleukin-2 muteins for the expansion of T-regulatory cells
CN114853874B (zh) *	2019-09-10	2024-05-17	中国医学科学院北京协和医院	靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
EP4073094A1 (en)	2019-12-12	2022-10-19	Iltoo Pharma	Interleukin 2 chimeric constructs
EP4090674A4 (en)	2020-01-14	2024-01-24	Synthekine, Inc.	Biased il2 muteins methods and compositions
US11981715B2 (en)	2020-02-21	2024-05-14	Pandion Operations, Inc.	Tissue targeted immunotolerance with a CD39 effector
TW202208395A (zh)	2020-05-12	2022-03-01	美商信號生物製藥公司	多聚體ｔ細胞調節多肽及其使用方法
KR102219927B1 (ko)	2020-05-20	2021-02-24	주식회사 카인사이언스	치료제로서의 펩타이드의 용도
AU2021287998B2 (en)	2020-06-11	2026-03-12	Benaroya Research Institute At Virginia Mason	Methods and compositions for preventing type 1 diabetes
KR102219928B1 (ko)	2020-06-26	2021-02-24	주식회사 카인사이언스	치료제로서의 펩타이드의 용도
EP4208474A2 (en) *	2020-09-01	2023-07-12	Takeda Pharmaceutical Company Limited	Interleukin-2 muteins and uses thereof
EP4211149A4 (en)	2020-09-09	2024-10-09	Cue Biopharma, Inc.	MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
EP4232071A4 (en)	2020-10-23	2024-08-28	Asher Biotherapeutics, Inc.	FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION
MX2023005030A (es)	2020-10-29	2023-05-16	Bristol Myers Squibb Co	Proteinas de fusion para el tratamiento de enfermedades.
EP4255466A1 (en) *	2020-12-04	2023-10-11	Visterra, Inc.	Methods of using interleukin-2 agents
CN112843222B (zh) *	2021-01-21	2023-01-31	暨南大学	Ankrd22蛋白在制备治疗或延缓自身免疫性疾病的产品中的应用
US12565529B2 (en)	2021-05-24	2026-03-03	Provention Bio, Inc.	Methods for treating type 1 diabetes
WO2023281485A1 (en)	2021-07-09	2023-01-12	Bright Peak Therapeutics Ag	Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
WO2023005680A1 (zh)	2021-07-30	2023-02-02	西安龙腾景云生物科技有限公司	一种人白细胞介素2变体及其用途
US20240376172A1 (en)	2021-10-06	2024-11-14	Iltoo Pharma	Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
WO2024056154A1 (en)	2022-09-12	2024-03-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Interleukin-2 for use in treating autism spectrum disorder
CN120529914A (zh)	2023-01-09	2025-08-22	奥德赛治疗股份有限公司	抗tnfr2抗原结合蛋白及其用途
WO2025217240A1 (en)	2024-04-10	2025-10-16	Odyssey Therapeutics, Inc.	Anti-tnfr2 antigen-binding proteins and uses thereof
WO2026006809A1 (en)	2024-06-27	2026-01-02	Odyssey Therapeutics, Inc.	Multispecific molecules binding tnfr2 and cd25 and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DZ2788A1 (fr)	1998-05-15	2003-12-01	Bayer Ag	Agonistes et antagonistes selectifs à IL-2.
US6955807B1 (en) *	1998-05-15	2005-10-18	Bayer Pharmaceuticals Corporation	IL-2 selective agonists and antagonists
US6348192B1 (en) *	1999-05-11	2002-02-19	Bayer Corporation	Interleukin-2 mutein expressed from mammalian cells
US6689353B1 (en)	2000-06-28	2004-02-10	Bayer Pharmaceuticals Corporation	Stabilized interleukin 2
US20060057651A1 (en) *	2000-12-08	2006-03-16	Bowdish Katherine S	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7371371B2 (en) *	2001-08-13	2008-05-13	University Of Southern California	Interleukin-2 mutants with reduced toxicity
PT1454138E (pt) *	2001-12-04	2012-03-28	Merck Patent Gmbh	Imunocitoquinas com seletividade modulada
US20060121029A1 (en) *	2002-08-30	2006-06-08	Hiroshi Shiku	Method and composition for regulating the activity of regulatory t cells
KR20050074492A (ko) *	2002-10-22	2005-07-18	와라타 파마수티컬즈, 인크.	당뇨병의 치료
EP1715889A4 (en) *	2004-01-08	2008-03-05	Univ California	LYMPHOCYTES T REGULATORS SUPPRESSING AUTOIMMUNITY
BRPI0508470A (pt) *	2004-03-05	2007-07-31	Chiron Corp	sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
DE202005001888U1 (de) *	2005-02-07	2005-07-28	Chiron Corp., Emeryville	Zusammensetzung, die Interleukin-2 und Natriumdodecylsulfat umfaßt
WO2009061853A2 (en)	2007-11-05	2009-05-14	Massachusetts Institute Of Technology	Mutant interleukin-2 (il-2) polypeptides
DE102008023820A1 (de)	2008-05-08	2009-11-12	Aicuris Gmbh & Co. Kg	Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen

2008
- 2008-05-08 DE DE102008023820A patent/DE102008023820A1/de not_active Withdrawn
2009
- 2009-04-28 PL PL09741834T patent/PL2288372T3/pl unknown
- 2009-04-28 UA UAA201014444A patent/UA102099C2/uk unknown
- 2009-04-28 EP EP09741834A patent/EP2288372B1/de active Active
- 2009-04-28 RU RU2010149999/15A patent/RU2531936C2/ru not_active IP Right Cessation
- 2009-04-28 HR HR20120296T patent/HRP20120296T1/hr unknown
- 2009-04-28 CN CN2009801266762A patent/CN102088996A/zh active Pending
- 2009-04-28 ES ES09741834T patent/ES2378957T3/es active Active
- 2009-04-28 JP JP2011507816A patent/JP5651583B2/ja not_active Expired - Fee Related
- 2009-04-28 KR KR1020107026580A patent/KR101554056B1/ko not_active Expired - Fee Related
- 2009-04-28 AU AU2009244039A patent/AU2009244039B2/en not_active Ceased
- 2009-04-28 PT PT09741834T patent/PT2288372E/pt unknown
- 2009-04-28 AT AT09741834T patent/ATE544465T1/de active
- 2009-04-28 CN CN201911154127.8A patent/CN110935025A/zh active Pending
- 2009-04-28 KR KR1020167020193A patent/KR20160092048A/ko not_active Withdrawn
- 2009-04-28 CA CA2723761A patent/CA2723761C/en not_active Expired - Fee Related
- 2009-04-28 DK DK09741834.7T patent/DK2288372T3/da active
- 2009-04-28 WO PCT/EP2009/003076 patent/WO2009135615A2/de not_active Ceased
- 2009-04-28 KR KR1020157013806A patent/KR101687506B1/ko not_active Expired - Fee Related
- 2009-04-28 MX MX2010012214A patent/MX2010012214A/es active IP Right Grant
- 2009-04-28 SI SI200930229T patent/SI2288372T1/sl unknown
- 2009-04-28 BR BRPI0912411A patent/BRPI0912411B8/pt not_active IP Right Cessation
- 2009-05-07 UY UY0001031816A patent/UY31816A/es not_active Application Discontinuation
- 2009-05-07 PE PE2009000635A patent/PE20091967A1/es not_active Application Discontinuation
- 2009-05-07 CL CL2009001099A patent/CL2009001099A1/es unknown
- 2009-05-07 TW TW098115067A patent/TWI510622B/zh not_active IP Right Cessation
- 2009-05-08 AR ARP090101665A patent/AR071756A1/es not_active Application Discontinuation
2010
- 2010-11-04 IL IL209128A patent/IL209128A/en active IP Right Grant
- 2010-11-08 US US12/941,885 patent/US20110150826A1/en not_active Abandoned
- 2010-11-12 ZA ZA2010/08129A patent/ZA201008129B/en unknown
2012
- 2012-03-08 CY CY20121100236T patent/CY1112469T1/el unknown
2014
- 2014-09-08 JP JP2014182422A patent/JP2015038084A/ja active Pending
2015
- 2015-06-26 US US14/752,726 patent/US9616105B2/en not_active Expired - Fee Related
2017
- 2017-02-05 IL IL250435A patent/IL250435A0/en unknown
- 2017-02-22 US US15/439,866 patent/US20170173117A1/en not_active Abandoned
- 2017-02-22 US US15/439,845 patent/US10086046B2/en not_active Expired - Fee Related
- 2017-08-02 IL IL253790A patent/IL253790A0/en unknown

Also Published As

Publication number	Publication date
AU2009244039B2 (en)	2014-04-17
KR20160092048A (ko)	2016-08-03
TW201006926A (en)	2010-02-16
EP2288372B1 (de)	2012-02-08
CN102088996A (zh)	2011-06-08
AR071756A1 (es)	2010-07-14
TWI510622B (zh)	2015-12-01
ES2378957T3 (es)	2012-04-19
RU2531936C2 (ru)	2014-10-27
CY1112469T1 (el)	2015-12-09
CA2723761C (en)	2019-01-22
CA2723761A1 (en)	2009-11-12
US20150374788A1 (en)	2015-12-31
AU2009244039A1 (en)	2009-11-12
RU2010149999A (ru)	2012-06-20
MX2010012214A (es)	2010-12-06
CN110935025A (zh)	2020-03-31
DE102008023820A1 (de)	2009-11-12
BRPI0912411A8 (pt)	2019-05-14
PE20091967A1 (es)	2010-02-05
US20170165326A1 (en)	2017-06-15
ZA201008129B (en)	2012-02-29
BRPI0912411B1 (pt)	2020-02-18
JP2015038084A (ja)	2015-02-26
KR101554056B1 (ko)	2015-09-18
US20110150826A1 (en)	2011-06-23
EP2288372A2 (de)	2011-03-02
UA102099C2 (uk)	2013-06-10
IL209128A0 (en)	2011-01-31
WO2009135615A8 (de)	2010-10-28
UY31816A (es)	2010-01-05
BRPI0912411B8 (pt)	2021-05-25
SI2288372T1 (sl)	2012-05-31
CL2009001099A1 (es)	2011-03-11
IL209128A (en)	2017-08-31
KR20150079824A (ko)	2015-07-08
KR101687506B1 (ko)	2016-12-16
WO2009135615A2 (de)	2009-11-12
IL250435A0 (en)	2017-03-30
IL253790A0 (en)	2017-09-28
US20170173117A1 (en)	2017-06-22
DK2288372T3 (da)	2012-04-02
KR20110015576A (ko)	2011-02-16
JP2011519882A (ja)	2011-07-14
ATE544465T1 (de)	2012-02-15
WO2009135615A3 (de)	2010-06-24
PL2288372T3 (pl)	2012-07-31
PT2288372E (pt)	2012-03-06
US9616105B2 (en)	2017-04-11
JP5651583B2 (ja)	2015-01-14
HRP20120296T1 (hr)	2012-04-30
US10086046B2 (en)	2018-10-02

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-03-26	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-08-13	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2019-12-24	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-02-18	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/02/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2022-02-22	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 13A ANUIDADE.
2022-06-07	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2668 DE 22-02-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0912411A2 (pt)	2016-09-13	uso de uma muteína de interleucina humana-2 (muteína de hil-2) ou de um fragmento da mesma, composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune, uso de muteína de interleucina humana-2 (muteína de hil-2) ou de uma seção da mesma, agete para formação de células t regulatórias (treg) em um organismo, método para tratamento e/ou profilaxia de uma doença autoimune em um organismo, método para formação de células t regulatórias (treg) em um organismo, método para formação de células t regulatórias (treg) in vitro.
BRPI0816097A2 (pt)	2016-11-01	composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.
BRPI0615150A2 (pt)	2017-06-20	agente para a profilaxia ou tratamento de diabete, sensibilizador de insulina, composto, pró-droga, agente farmacêutico, e, uso do composto ou um sal do mesmo ou uma pró-droga do mesmo
CL2011003346A1 (es)	2012-05-25	Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente.
BRPI0717697A2 (pt)	2016-03-22	composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos
BRPI0820967A2 (pt)	2015-07-14	Uso de uma composição, composição farmacêutica e método para tratamento, melhora ou profilaxia dos sintomas de uma doença inflamatória
BRPI0814503A2 (pt)	2017-05-16	composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica
CL2007002649A1 (es)	2008-04-11	Composicion farmaceutica que comprende 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo; y uso para el tratamiento de la diabetes.
BRPI0717219A2 (pt)	2015-05-26	"composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
BRPI0816255A2 (pt)	2015-03-17	Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
CL2007003520A1 (es)	2008-08-22	Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
DOP2010000304A (es)	2011-10-15	Composiciones y metodos de preparacion y uso de las mismas
CL2007003523A1 (es)	2008-08-22	Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
BRPI0820568A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal
EA202091999A2 (ru)	2021-01-29	Применение ингибиторов dpp iv
CY1112889T1 (el)	2016-04-13	Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης
BRPI0813311A2 (pt)	2014-12-23	Composto, métodos para modulara a atividade de uma proteína quinase e para tratar câncer em um indivíduo, e, composição farmacêutica.
BRPI0814957A2 (pt)	2015-02-03	Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto.
BR112013010829B8 (pt)	2022-01-04	Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
BR112012003462A2 (pt)	2016-02-23	"composto, composição farmacêutica, e, método para tratar um paciente tendo uma condição mediada pela proteína quinase."
CL2008000021A1 (es)	2009-03-27	Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
CO6280470A2 (es)	2011-05-20	Bis-piridilpiridonas como antaginistas del receptor 1 de la hormona concentradora de la melanina
EP4317179C0 (en)	2025-10-29	Dual GIP and GLP-1 receptor agonist, pharmaceutical composition and use
CL2008003546A1 (es)	2010-02-05	Compuestos derivados de piridina; procedimiento de preparacion; composicion farmaceutica de dichos compuestos; y uso en el tratamiento y/o profilaxis de la diabetes mellitus tipo i y/o tipo ii.
BRPI0509927A (pt)	2007-09-25	composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina